Tenax Therapeutics reports FY2023 net loss $7.7M; Phase 3 LEVEL trial underway

TENAX THERAPEUTICS, INC.

Cash $9.8M at Dec 31, 2023; Feb 2024 public offering netted ~$8.0M.
Net loss $7.7M (FY2023) vs $11.0M (FY2022); R&D expense down to $3.2M.
First patient enrolled in Phase 3 LEVEL study for TNX-103 (oral levosimendan) in PH-HFpEF.
Secured global commercial and IP rights for levosimendan in PH-HFpEF; topline data expected H2 2025.
KOL event 'LEVEL Setting' scheduled for April 18, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TENAX THERAPEUTICS, INC. reported year ended December 31, 2023 results: net income $7.7 million.

Period: year ended December 31, 2023
Net income: $7.7 million
Result: reported results

Exact text from the filing

Tenax Therapeutics reported a net loss for 2023 of $7.7 million

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

TENAX THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001654954-24-003775

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.